Company says it is ‘deeply concerned’ with the critical pandemic circumstances in IndiaBharat Biotech on Thursday announced a cut in price of its COVID-19 vaccine 'Covaxin' it plans to sell to the states to Rs 400 per dose from the earlier Rs 600. This follows a widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose. "Recognising the enormous challenges in the public healthcare system, we have made Covaxin available to state governments at a price of 400/ dose", Bharat Biotech said in its announcement. “As a philanthropic gesture on behalf of Serum Institute India, I hereby reduce the price to the states from Rs 400 to Rs 300 per dose, effective immediately; this will save thousands of crores of state funds going forward. States and private hospitals would have to procure their own vaccines at prices that would be fixed by the vaccine makers, it said.

Source: The Telegraph April 29, 2021 13:41 UTC